AstraZeneca and its global biologics research and development arm, MedImmune, will present new data on its respiratory portfolio and pipeline at the European Respiratory Society International this weekend in Milan, Italy.
Forty-eight accepted abstracts, including 11 oral presentations, which will focus on areas in asthma and chronic obstructive pulmonary disease (COPD).
Tom Keith-Roach, vice president, Respiratory at AstraZeneca, said: “The tezepelumab and benralizumab data at the ERS Congress represent the next generation of respiratory biologics that have the potential to truly transform asthma care by targeting the underlying causes of the disease. Respiratory is one of AstraZeneca’s three main therapy areas and we are excited to demonstrate the strength of our science and the breadth of our rapidly-expanding portfolio with 48 abstracts covering emerging science and new inhaled treatment paradigms.”
According to a release, highlights will include
- Advancing biologics in severe, uncontrolled asthma
- Growing body of data to support benralizumab – a potential new medicine for severe uncontrolled athsma.
- New evidence on the protective benefit of Symbicort(budesonide/formoterol) in some COPD patients.
- Breakthrough science in disease modification
- Breakthrough science in drug delivery technology
AstraZeneca has its North American commercial headquarters in north Wilmington.
AstraZeneca has been working to build a depleted drug pipeline by focusing on areas that include cancer, asthma, and diabetes.
